Activity of pemetrexed-based regimen as first-line chemotherapy for advanced non-small cell lung cancer with asymptomatic inoperable brain metastasis: a retrospective study

This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). A total of 30 patients with adenocarcinoma were included. Nine pa...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2015-08, Vol.27 (4), p.221-226
Main Authors: Zhu, Weiyou, Røe, Oluf Dimitri, Wu, Chen, Li, Wei, Guo, Renhua, Gu, Yanhong, Liu, Yiqian, Shu, Yongqian, Chen, Xiaofeng
Format: Article
Language:English
Subjects:
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Adenocarcinoma of Lung
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Brain - pathology
Brain metastasis
Brain Neoplasms - drug therapy
Carboplatin - administration & dosage
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Chemotherapy
Cisplatin - administration & dosage
Disease-Free Survival
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Male
Middle Aged
Non-small cell lung cancer
Pemetrexed
Pemetrexed - therapeutic use
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective study was conducted to assess the efficacy of combination of pemetrexed and cisplatin/carboplatin as first-line treatment in inoperable and asymptomatic brain metastasis (BM) from non-small cell lung cancer (NSCLC). A total of 30 patients with adenocarcinoma were included. Nine patients had solitary, and 21 patients had multiple BM. At evaluation after two cycles, the complete response (CR) rate, partial response (PR) rate, and stable disease (SD) for brain lesions was 0, 33.3, and 46.7%, respectively. The overall CR, PR, and SD were 0, 23.3, and 46.7%, respectively. The median time to tumour progression of BM (TTP-BM) was 6.0 months (95% CI 4.068-7.932). The median progression-free survival (PFS) and overall survival (OS) were 5.0 months (95% CI 4.197-5.803) and 11.0 months (95% CI 7.398-14.602), respectively. Pemetrexed has comparable activity on brain lesions as on extracranial tumours in advanced lung adenocarcinoma patients with inoperable and asymptomatic BM.
ISSN:1120-009X
1973-9478
DOI:10.1179/1973947815Y.0000000005